Web of Science: 80 citations, Scopus: 82 citations, Google Scholar: citations,
Recombinant pharmaceuticals from microbial cells : a 2015 update
Sanchez-Garcia, Laura (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Martín, Lucas (Universitat Autònoma de Barcelona. Technology Transfer Office)
Mangues, Ramon (Institut d'Investigacions Biomèdiques Sant Pau)
Ferrer-Miralles, Neus (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Vázquez, Esther (CIBER de Bioingeniería, Biomateriales y Nanomedicina (Barcelona))
Villaverde, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)

Date: 2016
Abstract: Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment.
Note: Altres ajuts: MARATÓ TV3: 2013-3930, 2013-132031
Note: Número d'acord de subvenció MINECO/BIO2013-41019P
Note: Número d'acord de subvenció AGAUR/2014/SGR-132
Note: Número d'acord de subvenció AGAUR/2014/PROD-00055
Note: Número d'acord de subvenció MINECO/PI12/00327
Note: Número d'acord de subvenció MINECO/PI15/00272
Note: Número d'acord de subvenció MINECO/PI15/00378
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Recombinant proteins ; Protein drugs ; Recombinant DNA ; Fusion proteins ; Biopharmaceuticals
Published in: Microbial Cell Factories, Vol. 15, Issue 33 (February 2016) , ISSN 1475-2859

PMID: 26861699
DOI: 10.1186/s12934-016-0437-3

7 p, 1.2 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles

 Record created 2018-02-07, last modified 2019-01-24

   Favorit i Compartir